Aranya Tomseth

Writer | Journalist

Recent New Drug Applications

June3

Here are the most recent drug applications submitted to the FDA for approval. I always find it interesting to see what’s coming our way.

  • Sancuso (granisetron) Transdermal Patch Company: ProStrakan Group; Treatment for: Nausea/Vomiting - Chemotherapy Induced. Sancuso (granisetron) is an anti-emetic transdermal delivery system in development for the treatment of chemotherapy-induced nausea and vomiting without the need for injections or swallowing pills.
  • Promacta (eltrombopag): Company: GlaxoSmithKline; Treatment for: Idiopathic (Immune) Thrombocytopenic Purpura. Promacta (eltrombopag) is an investigational oral platelet growth factor therapy for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura (ITP) to increase platelet counts and reduce or prevent bleeding.
  • Liraglutide Company: Novo Nordisk; Treatment for: Diabetes Mellitus Type II. Liraglutide is a once-daily human GLP-1 analogue in development for the treatment of people with type 2 diabete
  • Rezonic (casopitant): Company: GlaxoSmithKline; Treatment for: Nausea/Vomiting - Chemotherapy Induced, Nausea/Vomiting - Postoperative. Rezonic (casopitant) is an investigational NK-1 receptor antagonist in development as add-on therapy for the prevention of chemotherapy-induced nausea and vomiting, and also for the prevention of postoperative nausea and vomiting.
  • Surfaxin (lucinactant). Company: Discovery Laboratories, Inc. Treatment for: Respiratory Distress Syndrome. Surfaxin, an engineered version of natural human lung surfactant, represents a potential alternative to the commercially available animal-derived surfactants used for the prevention of Respiratory Distress Syndrome in premature infants.
  • OTG (oxybutynin hydrochloride) Topical Gel. Company: Watson Pharmaceuticals, Inc. Treatment for: Overactive Bladder
  • Viviant (bazedoxifene). Company: Wyeth Pharmaceuticals. Treatment for: Prevention of Osteoporosis. Viviant (bazedoxifene) is a selective estrogen receptor modulator (SERM) in development for the prevention of postmenopausal osteoporosis.
  • Davanat Company: Pro-Pharmaceuticals, Inc. Treatment for: Targeted Drug Delivery. Davanat is a polysaccharide polymer comprised of mannnose and galactose in development for the targeted delivery of drugs used in the treatment of cancer.
  • Reloxin (botulinum toxin type A) Company: Ipsen and Medicis. Treatment for: Aesthetics. Reloxin (botulinum toxin type A) is a neurotoxin in development for the temporary improvement in the appearance of some facial wrinkles.
  • Iclaprim Intravenous Injection. Company: Arpida Ltd. Treatment for: Skin and Structure Infection. Iclaprim is a broad-spectrum diaminopyrimidine antibiotic in development for the treatment of complicated skin and skin structure infections.
  • Sublinox (zolpidem) Sublingual Tablets. Company: Orexo and Meda AB. Sublinox is a sublingual tablet formulation of the widely used drug zolpidem. Sublinox is being developed to provide fast, effective absorption for the short term treatment of insomnia.
  • Entereg (alvimopan) Capsules. Company: Adolor Corporation. Treatment for: Postoperative Ileus. Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.
  • Cinryze (C1 inhibitor). Company: Lev Pharmaceuticals, Inc. Treatment for: Angioedema. Cinryze is a C1-esterase inhibitor being developed as a comprehensive replacement therapy for the treatment of hereditary angioedema (HAE).
  • Naturlose (tagatose). Company: Spherix Incorporated. Treatment for: Diabetes Mellitus Type II. Naturlose (tagatose) is a unique sugar undergoing clinical trials as a treatment for Type 2 diabetes.
  • Imagify (perflubutane). Company: Acusphere Inc. Imagify is an investigational new drug developed to assess perfusion using ultrasound (or echocardiography) for the detection of coronary artery disease.
  • MK-0524A (niacin ER and laropiprant) - formerly Cordaptive. Company: Merck & Co., Inc. Treatment for: Hyperlipoproteinemia Type IIa (Elevated LDL), Hypertriglyceridemia. MK-0524A is an investigational compound containing extended-release niacin and laropiprant, a novel flushing pathway inhibitor designed to reduce flushing often associated with niacin treatment. MK-0524A is used either alone or with a statin, as adjunctive therapy to diet for the treatment of elevated LDL cholesterol, low HDL cholesterol and elevated triglyceride levels.
posted under FDA, New Drugs, Uncategorized

Email will not be published

Website example

Your Comment: